Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

High throughput phenotypic screen and transcriptional analysis identify new compounds, targets and pathways for macrophage reprogramming I

ABSTRACT: Purpose: To understand compound effects on human macrophage polarization in the transcriptional level

ORGANISM(S): Homo sapiens

PROVIDER: GSE144989 | GEO | 2020/08/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Shared Molecules

Only show the datasets with similarity scores above: 0.5

Threshold

0.5

Similar Datasets

High throughput phenotypic screen and transcriptional analysis identify new compounds, targets and pathways for macrophage reprogramming III

Project description:Purpose: To understand the effects of signaling ligands on human macrophage polarization in the transcriptional level

2020-08-05 | GSE144991 | GEO

High throughput phenotypic screen and transcriptional analysis identify new compounds, targets and pathways for macrophage reprogramming II

Project description:Purpose: To understand compound effects on human macrophage repolarization in the transcriptional level

2020-08-05 | GSE144990 | GEO

High-throughput phenotypic screen and transcriptional analysis identify new compounds and targets for macrophage reprogramming.

Project description:Macrophages are plastic and, in response to different local stimuli, can polarize toward multi-dimensional spectrum of phenotypes, including the pro-inflammatory M1-like and the anti-inflammatory M2-like states. Using a high-throughput phenotypic screen in a library of ~4000 FDA-approved drugs, bioactive compounds and natural products, we find ~300 compounds that potently activate primary human macrophages toward either M1-like or M2-like state, of which ~30 are capable of reprogramming M1-like macrophages toward M2-like state and another ~20 for the reverse repolarization. Transcriptional analyses of macrophages treated with 34 non-redundant compounds identify both shared and unique targets and pathways through which the tested compounds modulate macrophage activation. One M1-activating compound, thiostrepton, is able to reprogram tumor-associated macrophages toward M1-like state in mice, and exhibit potent anti-tumor activity. Our compound-screening results thus help to provide a valuable resource not only for studying the macrophage biology but also for developing therapeutics through modulating macrophage activation.

| S-EPMC7858590 | biostudies-literature

High throughput phenotypic screen and transcriptional analysis identify new compounds, targets and pathways for macrophage reprogramming

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-08-05 | GSE144992 | GEO

High throughput phenotypic screen and transcriptional analysis identify new compounds, targets and pathways for macrophage reprogramming

Project description:High throughput phenotypic screen and transcriptional analysis identify new compounds, targets and pathways for macrophage reprogramming

| PRJNA605636 | ENA

High throughput phenotypic screen and transcriptional analysis identify new compounds, targets and pathways for macrophage reprogramming III

Project description:High throughput phenotypic screen and transcriptional analysis identify new compounds, targets and pathways for macrophage reprogramming III

| PRJNA605638 | ENA

High throughput phenotypic screen and transcriptional analysis identify new compounds, targets and pathways for macrophage reprogramming I

Project description:High throughput phenotypic screen and transcriptional analysis identify new compounds, targets and pathways for macrophage reprogramming I

| PRJNA605634 | ENA

High throughput phenotypic screen and transcriptional analysis identify new compounds, targets and pathways for macrophage reprogramming II

Project description:High throughput phenotypic screen and transcriptional analysis identify new compounds, targets and pathways for macrophage reprogramming II

| PRJNA605639 | ENA

A Yeast/Drosophila Screen to Identify New Compounds Overcoming Frataxin Deficiency.

Project description:Friedreich's ataxia (FA) is a rare neurodegenerative disease which is very debilitating for the patients who progressively lose their autonomy. The lack of efficient therapeutic treatment of the disease strongly argues for urgent need to search for new active compounds that may stop the progression of the disease or prevent the appearance of the symptoms when the genetic defect is diagnosed early enough. In the present study, we used a yeast strain with a deletion of the frataxin homologue gene as a model of FA cells in a primary screen of two chemical libraries, a fraction of the French National Chemical Library (5500 compounds) and the Prestwick collection (880 compounds). We ran a secondary screen on Drosophila melanogaster flies expressing reduced levels of frataxin during larval development. Half of the compounds selected in yeast appeared to be active in flies in this developmental paradigm, and one of the two compounds with highest activities in this assay partially rescued the heart dilatation phenotype resulting from heart specific depletion of frataxin. The unique complementarity of these two frataxin-deficient models, unicellular and multicellular, appears to be very efficient to select new compounds with improved selectivity, bringing significant perspectives towards improvements in FA therapy.

| S-EPMC4619980 | biostudies-literature

A 1536-well quantitative high-throughput screen to identify compounds targeting cancer stem cells.

Project description:Tumor cell subpopulations called cancer stem cells (CSCs) or tumor-initiating cells (TICs) have self-renewal potential and are thought to drive metastasis and tumor formation. Data suggest that these cells are resistant to current chemotherapy and radiation therapy treatments, leading to cancer recurrence. Therefore, finding new drugs and/or drug combinations that cause death of both the differentiated tumor cells as well as CSC populations is a critical unmet medical need. Here, we describe how cancer-derived CSCs are generated from cancer cell lines using stem cell growth media and nonadherent conditions in quantities that enable high-throughput screening (HTS). A cell growth assay in a 1536-well microplate format was developed with these CSCs and used to screen a focused collection of oncology drugs and clinical candidates to find compounds that are cytotoxic against these highly aggressive cells. A hit selection process that included potency and efficacy measurements during the primary screen allowed us to efficiently identify compounds with potent cytotoxic effects against spheroid-derived CSCs. Overall, this research demonstrates one of the first miniaturized HTS assays using CSCs. The procedures described here should enable further testing of the effect of compounds on CSCs and help determine which pathways need to be targeted to kill them.

| S-EPMC6993186 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data